SCTC21C

Phase 3Biologic

SSinocelltech Ltd.

SCTC21C is one of 100 biologic programs targeting Amyloidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmyloidosisActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Multiple MyelomaActive, not recruiting

AmyloidosisPhase 3

Active, not recruiting

Autoimmune DiseasePhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

SCTC21C

SSinocelltech Ltd.

Phase 3

1 2

Ninlaro

Takeda

Preclinical

18 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Intron a

Systemic Therapy

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hematologic Malignancies

NCT06252298

Q4 2028

Phase 3Recruiting

Multiple Myeloma

NCT07297329

Phase 3Recruiting

Amyloidosis

NCT07388602

Q1 2029

Phase 1/2Not yet recruiting

Autoimmune Disease

NCT06774664

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting·SSinocelltech Ltd.·Phase 1·NCT06252298·74 enrolled

Multiple Myeloma1 trial

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07297329·292 enrolled

Autoimmune Disease1 trial

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not yet recruiting·SSinocelltech Ltd.·Phase 1/2·NCT06774664·99 enrolled

Amyloidosis1 trial

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07388602·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SCTC21C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCTC21C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCTC21C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinocelltech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSinocelltech Ltd.

SCTC21C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Hematologic Malignancies1 trial

Multiple Myeloma1 trial

Autoimmune Disease1 trial

Amyloidosis1 trial

References

Drug Info

Quick Facts

Related News